Sanofi is ending research efforts in diabetes and cardiovascular diseases; the White House endorsed an emerging bipartisan agreement on legislation aimed at curbing rising healthcare costs by targeting surprise medical billing; the Supreme Court will hear oral arguments in a case involving whether the federal government owes insurers $12 billion in a dispute about risk corridor payments.
Sanofi is ending research efforts in diabetes and cardiovascular diseases, Reuters reported. The French drug giant also said it is buying US biotechnology firm Synthorx for about $2.5 billion to focus on oncology drugs. The moves are part of a revamp to narrow the number of its business units in an effort to grow profits. The company dominated the insulin market before it was hit by patent losses and a drop in sales.The White House endorsed an emerging bipartisan agreement on legislation aimed at curbing rising healthcare costs, The Associated Press reported. The legislation would limit surprise medical bills by establishing a system of arbitration aimed at resolving disputes. Congress is scheduled to remain in session for 2 more weeks before adjourning for the year, and it is uncertain if the bill can be approved within that window.The Supreme Court will hear oral arguments in a case involving whether the federal government owes insurers $12 billion in a dispute about risk corridor payments. The payments sought to mitigate risk by protecting insurers against unforeseeable losses in the new exchange markets created by the Affordable Care Act. The Hill reported that the case puts the Trump administration “in the awkward position of having to pay out billions even as it fights to end the law.”
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More